X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (997) 997
Newsletter (183) 183
Newspaper Article (127) 127
Magazine Article (15) 15
Publication (14) 14
Book Chapter (10) 10
Streaming Video (3) 3
Transcript (2) 2
Conference Proceeding (1) 1
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
dapagliflozin (1338) 1338
type 2 diabetes (650) 650
science & technology (508) 508
life sciences & biomedicine (491) 491
diabetes (413) 413
glucose (334) 334
humans (310) 310
research (249) 249
dextrose (228) 228
endocrinology & metabolism (224) 224
diabetes mellitus, type 2 - drug therapy (220) 220
diabetes therapy (209) 209
drug therapy (183) 183
care and treatment (182) 182
male (175) 175
medical research (175) 175
diabetes mellitus (174) 174
medicine, experimental (167) 167
glucosides - therapeutic use (166) 166
heart failure (163) 163
analysis (162) 162
canagliflozin (161) 161
clinical trials (156) 156
female (150) 150
hypoglycemic agents - therapeutic use (142) 142
empagliflozin (137) 137
pharmacology & pharmacy (137) 137
benzhydryl compounds - therapeutic use (135) 135
middle aged (135) 135
pharmaceutical industry (133) 133
sglt2 inhibitor (122) 122
insulin (120) 120
risk factors (118) 118
physical fitness (116) 116
type 2 diabetes mellitus (112) 112
sodium-glucose transporter 2 - antagonists & inhibitors (109) 109
treatment outcome (96) 96
dosage and administration (94) 94
aged (93) 93
glucosides - adverse effects (93) 93
metformin (93) 93
animals (85) 85
adult (81) 81
glucosides - pharmacology (81) 81
benzhydryl compounds - adverse effects (80) 80
hypoglycemic agents - adverse effects (79) 79
blood pressure (78) 78
patients (78) 78
sodium (76) 76
hypoglycemia (75) 75
type 1 diabetes (75) 75
body weight (74) 74
glucosides - administration & dosage (73) 73
cardiac patients (72) 72
hyperglycemia (72) 72
metabolism (71) 71
sglt2 inhibitors (71) 71
blood glucose - drug effects (69) 69
cardiovascular diseases (69) 69
internal medicine (68) 68
kidney diseases (68) 68
diabetics (67) 67
blood glucose - metabolism (64) 64
insulin resistance (64) 64
saxagliptin (64) 64
benzhydryl compounds - administration & dosage (62) 62
hypoglycemic agents - administration & dosage (61) 61
benzhydryl compounds - pharmacology (60) 60
cardiovascular system & cardiology (60) 60
health aspects (60) 60
cardiovascular disease (59) 59
glycosylated hemoglobin (59) 59
chronic kidney failure (57) 57
drug therapy, combination (57) 57
hypoglycemic agents (57) 57
complications and side effects (56) 56
hypoglycemic agents - pharmacology (55) 55
sglt2 (55) 55
usage (55) 55
endocrinology (54) 54
general & internal medicine (54) 54
urinary tract infections (54) 54
diabetes mellitus, type 2 - complications (53) 53
medicine & public health (53) 53
physiological aspects (53) 53
double-blind method (52) 52
medicine, general & internal (52) 52
obesity (52) 52
benzhydryl compounds (51) 51
diabetes mellitus, type 2 - blood (51) 51
mortality (51) 51
original (50) 50
sodium-glucose transporter 2 - metabolism (50) 50
cardiac & cardiovascular systems (49) 49
drug approval (49) 49
sodium-glucose transporter 2 inhibitors - therapeutic use (48) 48
blood sugar (46) 46
diabetes mellitus, type 2 - metabolism (46) 46
hemoglobin (46) 46
hypertension (46) 46
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1315) 1315
Spanish (10) 10
Chinese (7) 7
Czech (7) 7
German (7) 7
Russian (6) 6
Korean (5) 5
Japanese (4) 4
French (2) 2
Hungarian (1) 1
Norwegian (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nephrology, dialysis, transplantation, ISSN 1460-2385, 11/2018, Volume 33, Issue 11, pp. 2005 - 2011
Background. The sodium-glucose co-transporter 2 inhibitor dapagliflozin decreases haemoglobin A1c (HbA1c), body weight, blood pressure (BP) and urinary... 
LONG-TERM | METFORMIN | SGLT2 INHIBITORS | dapagliflozin | 28-WEEK EXTENSION | 24-WEEK | MELLITUS | SGLT2 inhibitor | INADEQUATE GLYCEMIC CONTROL | kidney | type 2 diabetes | DOUBLE-BLIND | CARDIOVASCULAR-DISEASE | PLACEBO-CONTROLLED TRIAL | diabetic nephropathy
Journal Article
Cardiovascular diabetology, ISSN 1475-2840, 10/2017, Volume 16, Issue 1, pp. 138 - 138
Background: Sodium-glucose cotransporter-2 inhibitors reduce blood pressure (BP) and renal and cardiovascular events in patients with type 2 diabetes through... 
Type 2 diabetes | Flow-mediated dilation | Dapagliflozin | Thiazide diuretics | Pulse wave velocity | SGLT2-inhibitors | Resistive index | Endothelium | Cardiac & Cardiovascular Systems | Endocrinology & Metabolism | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Blood Glucose - physiology | Kidney - blood supply | Humans | Middle Aged | Endothelium, Vascular - drug effects | Male | Vascular Resistance - physiology | Vascular Resistance - drug effects | Adult | Female | Glucosides - therapeutic use | Blood Pressure - drug effects | Blood Pressure - physiology | Benzhydryl Compounds - therapeutic use | Kidney - physiopathology | Glucosides - pharmacology | Kidney - drug effects | Endothelium, Vascular - physiopathology | Sodium-Glucose Transporter 2 - antagonists & inhibitors | Blood Glucose - drug effects | Diabetes Mellitus, Type 2 - blood | Pilot Projects | Diabetes Mellitus, Type 2 - physiopathology | Vascular Stiffness - drug effects | Vascular Stiffness - physiology | Aged | Benzhydryl Compounds - pharmacology | Diabetes Mellitus, Type 2 - drug therapy | Cohort Studies | Diuresis | Oxidative stress | Renal function | Glucose | Metabolic syndrome | Vasodilation | Ultrasonic imaging | Mathematical analysis | Rodents | Atherosclerosis | Aorta | Stiffness | Blood pressure | Magnesium | Diabetes mellitus (non-insulin dependent) | Hypertension | Kidneys | Diabetes mellitus | Mortality | Hydrochlorothiazide | Patients | Chemical compounds | Variance analysis | Velocity | Studies | Isoprostanes | Sodium | Dilation | Flow velocity | Gastrointestinal surgery | Diabetes | Wave velocity | Veins & arteries | Index Medicus
Journal Article
The New England journal of medicine, ISSN 1533-4406, 01/2019, Volume 380, Issue 4, pp. 347 - 357
In a randomized trial of patients with type 2 diabetes, treatment with dapagliflozin, an SGLT2 inhibitor that promotes glucosuria, did not result in a higher... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Cardiovascular Diseases - etiology | Sodium-Glucose Transporter 2 Inhibitors - therapeutic use | Sodium-Glucose Transporter 2 Inhibitors - adverse effects | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Hospitalization - statistics & numerical data | Male | Benzhydryl Compounds - adverse effects | Cardiovascular Diseases - mortality | Female | Glucosides - therapeutic use | Aged | Diabetes Mellitus, Type 2 - drug therapy | Benzhydryl Compounds - therapeutic use | Heart Failure - epidemiology | Diabetes Mellitus, Type 2 - complications | Glucosides - adverse effects | Type 2 diabetes | Safety and security measures | Dapagliflozin | Dosage and administration | Drug therapy | Cardiovascular diseases | Risk factors | Heart failure | Myocardial infarction | Cerebral infarction | End-stage renal disease | Heart attacks | Mortality | Diabetes mellitus | Cardiovascular disease | FDA approval | Patients | Glomerular filtration rate | Heart rate | Ischemia | Sodium | Arteriosclerosis | Ketoacidosis | Death | Diabetes | Kidney diseases | Safety | Diabetes mellitus (non-insulin dependent) | Heart diseases | Index Medicus | Abridged Index Medicus | Life Sciences | Food and Nutrition | Animal biology | Cellular Biology | Pharmaceutical sciences | Cardiovascular Diseases | drug therapy | Benzhydryl Compounds | complications | Sodium-Glucose Transporter 2 Inhibitors | Hospitalization | prevention & control | Klinisk medicin | Diabetes Mellitus | etiology | Clinical Medicine | epidemiology | statistics & numerical data | adverse effects | mortality | Type 2 | Heart Failure | therapeutic use | Glucosides
Journal Article
The New England journal of medicine, ISSN 1533-4406, 11/2019, Volume 381, Issue 21, pp. 1995 - 2008
In this randomized, placebo-controlled trial, investigators evaluated the effects of the sodium–glucose cotransporter 2 inhibitor dapagliflozin in patients... 
NEPRILYSIN INHIBITION | OUTCOMES | COTRANSPORTER 2 INHIBITORS | MECHANISM | EMPAGLIFLOZIN | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Glycated Hemoglobin A - analysis | Humans | Middle Aged | Ventricular Dysfunction, Left - complications | Male | Benzhydryl Compounds - adverse effects | Cardiovascular Diseases - mortality | Female | Glucosides - therapeutic use | Drug Therapy, Combination | Benzhydryl Compounds - therapeutic use | Diabetes Mellitus, Type 2 - complications | Glucosides - adverse effects | Heart Failure - complications | Sodium-Glucose Transporter 2 Inhibitors - therapeutic use | Sodium-Glucose Transporter 2 Inhibitors - adverse effects | Kaplan-Meier Estimate | Stroke Volume - drug effects | Combined Modality Therapy | Hospitalization | Heart Failure - drug therapy | Cardiovascular Agents - therapeutic use | Diabetes Mellitus, Type 2 - blood | Ventricular Dysfunction, Left - drug therapy | Aged | Diabetes Mellitus, Type 2 - drug therapy | Type 2 diabetes | Measurement | Heart failure | Dapagliflozin | Patient outcomes | Physiological aspects | Cardiac output | Drug therapy | Testing | Intravenous administration | Renal function | Clinical trials | Hypoglycemia | Evidence-based medicine | Clinical outcomes | Sodium | Hemoglobin | Patient safety | Diabetes | Diabetes mellitus (non-insulin dependent) | Heart diseases | Drug dosages | Ejection fraction | Index Medicus | Abridged Index Medicus | Kardiologi | Clinical Medicine | Cardiac and Cardiovascular Systems | Medical and Health Sciences | Klinisk medicin | Medicin och hälsovetenskap
Journal Article
Nephrology, dialysis, transplantation, ISSN 0931-0509, 04/2019, Volume 35, Issue 9, pp. 1570 - 1576
Besides improving glucose control, sodium-glucose co-transporter 2 inhibition with dapagliflozin reduces blood pressure, body weight and urinary... 
Index Medicus | clinical trial | diabetic kidney disease | heart failure | risk markers | Editor's Choice | dapagliflozin | AcademicSubjects | Original | MED00340
Journal Article
Circulation (New York, N.Y.), ISSN 1524-4539, 05/2019, Volume 139, Issue 22, pp. 2528 - 2536
Journal Article
Atención primaria, ISSN 0212-6567, 10/2015, Volume 47, Issue 8, pp. 505 - 513
Objective To assess the efficiency of the combined therapy with metformin and dapagliflozin, a new oral anti-diabetic drug with an insulin-independent... 
Costs | Diabetes | DPP4 inhibitors | Dapagliflozin | Thiazolidinediones | Sulphonylureas
Journal Article
Diabetes, obesity & metabolism, ISSN 1462-8902, 09/2013, Volume 15, Issue 9, pp. 853 - 862
Journal Article